Submitted by dcc on Fri, 2021-06-04 12:51 Study Title: A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)CIRB: Adult CIRB - Early Phase EmphasisLead Group: ETCTNStatus: ActiveReview Status: Available to Open
